{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Gujarat Terce Laboratories Ltd
Gujarat Terce Laboratories Ltd is Rated Strong Sell
Gujarat Terce Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 07 February 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Are Gujarat Terce Laboratories Ltd latest results good or bad?
Gujarat Terce Laboratories Ltd's latest results are concerning, showing a 4.95% decline in net sales and a 45.71% drop in net profit, indicating significant operational challenges and margin compression. The company struggles to maintain consistent profitability despite a diverse product portfolio.
Gujarat Terce Laboratories Ltd Reports Flat Quarterly Performance Amid Margin Pressures
Gujarat Terce Laboratories Ltd has reported a flat financial performance for the quarter ended December 2025, marking a significant shift from its previously positive growth trajectory. Despite a modest increase in profit after tax (PAT) over the last six months, the company’s overall financial trend score has deteriorated sharply, reflecting challenges in sustaining revenue growth and margin expansion in a competitive pharmaceutical sector.
Gujarat Terce Laboratories Q3 FY26: Profitability Collapse Raises Serious Concerns
Gujarat Terce Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹33.00 crores, has reported deeply concerning quarterly results that highlight mounting operational challenges. The company's net profit collapsed by 71.88% quarter-on-quarter in Q2 FY26 to ₹0.45 crores, whilst posting a modest year-on-year improvement of 21.62%. The stock, trading at ₹46.34, has plunged 43.76% over the past year, significantly underperforming both the Sensex and the broader pharmaceuticals sector.
Gujarat Terce Laboratories Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals
Gujarat Terce Laboratories Ltd has been downgraded from a Sell to a Strong Sell rating as of 19 Jan 2026, reflecting deteriorating technical indicators, expensive valuation metrics, and weak long-term fundamentals despite some recent positive financial results and rising promoter confidence.
Gujarat Terce Laboratories Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals
Gujarat Terce Laboratories Ltd has seen its investment rating upgraded from Strong Sell to Sell, driven primarily by a shift in technical indicators from mildly bearish to sideways, signalling a potential stabilisation in price action. However, the company’s fundamental challenges, including weak long-term growth and expensive valuation metrics, continue to weigh on investor sentiment.
Gujarat Terce Laboratories Ltd is Rated Strong Sell
Gujarat Terce Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 09 Dec 2025. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock’s current position as of 26 December 2025, providing investors with the latest insights into the company’s fundamentals, valuation, financial trend, and technical outlook.
Why is Guj. Terce Labs. falling/rising?
On 19-Dec, Gujarat Terce Laboratories Ltd witnessed a notable rise in its share price, climbing 5.85% to close at ₹48.15, reflecting a strong short-term performance despite a challenging year-to-date and one-year backdrop.
Gujarat Terce Laboratories: Analytical Perspective Shifts Amid Mixed Financial and Technical Signals
Gujarat Terce Laboratories has experienced a revision in its market assessment driven by nuanced changes across quality, valuation, financial trends, and technical indicators. Despite recent positive quarterly financial results, the company’s longer-term fundamentals and technical outlook present a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector.
Gujarat Terce Laboratories Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals
Gujarat Terce Laboratories has experienced a notable revision in its market evaluation, reflecting a complex interplay of technical indicators and fundamental financial data. While recent trading activity shows signs of stabilisation, underlying financial metrics continue to present challenges, prompting a nuanced reassessment of the company's investment profile.
How has been the historical performance of Guj. Terce Labs.?
Guj. Terce Labs has experienced a decline in net sales and profitability over the past three years, culminating in a loss of -2.52 Cr in the most recent fiscal year, with significant decreases in revenue and operating profit. The company's financial metrics indicate ongoing challenges in generating cash from core operations.
Is Guj. Terce Labs. overvalued or undervalued?
As of November 17, 2025, Guj. Terce Labs. is considered very expensive and overvalued, with a PE ratio of -32.23 and poor stock performance, significantly lagging behind peers like Sun Pharma and Divi's Lab.
How has been the historical performance of Guj. Terce Labs.?
Guj. Terce Labs has experienced a decline in net sales and profitability over the past three years, culminating in a loss of 2.52 Cr in the most recent fiscal year. However, there has been a notable recovery in cash flow activities in the latest fiscal year.
Are Guj. Terce Labs. latest results good or bad?
Gujarat Terce Laboratories' latest Q2 FY26 results are concerning, showing flat revenue growth and a significant decline in operating profit margins and net profit, indicating serious operational challenges and weak market confidence. The company's financial health is further stressed by high employee costs and a fully pledged promoter stake.
Gujarat Terce Laboratories Q2 FY26: Profit Plunge Raises Serious Concerns
Gujarat Terce Laboratories Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹32.00 crores, reported deeply concerning quarterly results for Q2 FY26 (Jul-Sep'25), with net profit plummeting 71.88% quarter-on-quarter to ₹0.45 crores from ₹1.60 crores in Q1 FY26. The stock, currently trading at ₹45.98, has collapsed 45.25% over the past year, significantly underperforming both the broader market and its pharmaceutical sector peers.
Why is Guj. Terce Labs. falling/rising?
As of 06-Nov, Gujarat Terce Laboratories Ltd's stock price is Rs 44.15, down 3.73%, and has significantly underperformed with a 47.94% decline year-to-date, contrasting sharply with the Sensex's 6.62% gain. The stock is trading below key moving averages and has seen a drastic drop in investor interest, with delivery volume down 83.32% against the 5-day average.
Why is Guj. Terce Labs. falling/rising?
As of 30-Oct, Gujarat Terce Laboratories Ltd's stock price is Rs 47.15, down 2.98%, with a significant year-to-date decline of 44.40%. Despite underperforming compared to the benchmark Sensex, there has been a 40.33% increase in delivery volume, indicating some investor interest.
Why is Guj. Terce Labs. falling/rising?
As of 24-Oct, Gujarat Terce Laboratories Ltd's stock price is Rs 50.00, down 5.27%, with a significant intraday low of Rs 49.02. Despite a 2.04% gain over the past week, it has a year-to-date decline of 41.04%, indicating underperformance compared to the broader market.
Why is Guj. Terce Labs. falling/rising?
As of 23-Oct, Gujarat Terce Laboratories Ltd's stock price is Rs 53.00, up 3.31% recently, with strong short-term gains but significant long-term declines of 37.50% year-to-date and 30.26% over the past year. Despite recent outperformance against the Sensex, the stock has faced pressure in the longer term, contrasting with its impressive three and five-year returns.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
